Live Breaking News & Updates on High Performing Vidofludimus Calcium

Stay updated with breaking news from High performing vidofludimus calcium. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Immunic Reports Positive Data from Maintenance Phase of Phase 2 CALDOSE-1 Trial of Vidofludimus Calcium in Moderate-to-Severe Ulcerative Colitis

– 50-Week Maintenance Phase Data Shows Dose-Linear Increase in Clinical Remission for Vidofludimus Calcium as Compared to Placebo – – 30 mg Once-Daily Dose of. ....

United States , Andreas Muehler , Jessica Breu , Daniel Vitt , Deprioritize Izumerogant , Edna Kaplan , Paula Schwartz , Exchange Commission , Rx Communications Group , Development Programs , Prnewswire Immunic Inc , Immunic Inc , Clinical Remission , Vidofludimus Calcium , Once Daily Dose , Endoscopic Healing , High Performing Vidofludimus Calcium , Immunic Decided , Conference Call , Chief Executive Officer , Chief Medical Officer , Eastern Europe , Private Securities Litigation Reform Act , Annual Report , Investor Relations ,

EQS-News: Immunic, Inc.: Immunic Reports Positive Data from Maintenance Phase of Phase 2 CALDOSE-1 Trial of Vidofludimus Calcium in Moderate-to-Severe Ulcerative Colitis

Issuer: Immunic, Inc. / Key word(s): Study results/Strategic Company Decision Immunic Reports Positive Data from Maintenance Phase of Phase 2 CALDOSE-1 Trial of Vidofludimus Calcium in Moderate-to-Severe ....

United States , Paula Schwartz , Andreas Muehler , Deprioritize Izumerogant , Jessica Breu , Edna Kaplan , Daniel Vitt , Exchange Commission , Distribution Services , Strategic Company Decision , Development Programs , Immunic Inc , Rx Communications Group , Reports Positive Data , Maintenance Phase , Vidofludimus Calcium , Moderate To Severe Ulcerative Colitis , Moderate To Severe Ulcerative , Clinical Remission , Once Daily Dose , Endoscopic Healing , Focus Resources , High Performing Vidofludimus Calcium , Immunic Decided , Chief Executive Officer , Chief Medical Officer ,

EQS-News: Immunic Reports Positive Data from Maintenance Phase of Phase 2 CALDOSE-1 Trial of Vidofludimus Calcium in Moderate-to-Severe Ulcerative Colitis

Issuer: Immunic, Inc. / Key word(s): Study results/Strategic Company Decision Immunic Reports Positive Data from Maintenance Phase of Phase 2 CALDOSE-1 Trial of Vidofludimus Calcium in Moderate-to-Severe Ulcerative Colitis 05.04.2023 / 12:30 CET/CEST The issuer is solely responsible for the cont. ....

United States , Daniel Vitt , Edna Kaplan , Jessica Breu , Andreas Muehler , Paula Schwartz , Deprioritize Izumerogant , Rx Communications Group , Exchange Commission , Strategic Company Decision , Distribution Services , Immunic Inc , Development Programs , Reports Positive Data , Maintenance Phase , Vidofludimus Calcium , Moderate To Severe Ulcerative Colitis , Moderate To Severe Ulcerative , Clinical Remission , Once Daily Dose , Endoscopic Healing , High Performing Vidofludimus Calcium , Immunic Decided , Conference Call , Chief Executive Officer , Chief Medical Officer ,